Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990802 | 0.86 | SMO (0.47) | AKT1SMN1; SMN2MEN1KMT2AHTR3A | |
| SCHEMBL990764 | 0.82 | MAPT (0.45) | AKT1SMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL22652074 | 0.82 | HTR3A (0.49) | HTR3AHRH4HRH3 | |
| SCHEMBL27658351 | 0.79 | HRH4 (0.40) | HTR3AIKBKBRAB9AL3MBTL1HRH4 | |
| SCHEMBL3557669 | 0.78 | MAPT (0.49) | SMN1; SMN2MEN1KMT2AALDH1A1HRH3 | |
| SCHEMBL27678428 | 0.75 | HTR3A (0.48) | HTR3AHRH4HRH3 | |
| SCHEMBL989988 | 0.74 | HTR3A (0.39) | HTR3ARAB9AL3MBTL1HRH4HRH3 | |
| SCHEMBL992615 | 0.74 | HTR3A (0.43) | HTR3AIKBKBRAB9AL3MBTL1HRH4 | |
| SCHEMBL14938526 | 0.72 | HTR3A (0.53) | KMT2AHTR3AHRH4HRH3 | |
| SCHEMBL29464176 | 0.72 | HTR3A (0.53) | KMT2AHTR3AHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745037-B1 | Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases | NOVARTIS AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| EP-2270001-A1 | Indolylmaleimide derivatives as PKC inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-7648989-B2 | Indolylmaleimide derivatives as PKC inhibitors | NOVARTIS AG (CH) | 2010-01-19 | — | — | US | disclosed |
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| EP-1745037-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PKC INHIBITORS | Novartis AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005068455-A1 | INDOLYLMALEIMDE DERIVATIVES AS PKC INHIBITORS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | PRKCE, PRKCH, PRKCI | AKT1 248/4885SMN1; SMN2 4485/4885MEN1 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.